HighTower Advisors LLC Boosts Stock Holdings in Cue Biopharma, Inc. (NASDAQ:CUE)

HighTower Advisors LLC lifted its position in shares of Cue Biopharma, Inc. (NASDAQ:CUE) by 54.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 128,284 shares of the company’s stock after buying an additional 45,000 shares during the period. HighTower Advisors LLC’s holdings in Cue Biopharma were worth $140,000 as of its most recent SEC filing.

Separately, Geode Capital Management LLC raised its holdings in shares of Cue Biopharma by 3.3% in the 3rd quarter. Geode Capital Management LLC now owns 508,827 shares of the company’s stock worth $385,000 after purchasing an additional 16,371 shares during the period. 35.04% of the stock is owned by institutional investors and hedge funds.

Cue Biopharma Stock Down 11.2 %

Shares of NASDAQ:CUE opened at $0.68 on Friday. Cue Biopharma, Inc. has a 1 year low of $0.45 and a 1 year high of $2.26. The stock has a 50-day simple moving average of $1.16 and a 200-day simple moving average of $1.18. The company has a debt-to-equity ratio of 0.05, a quick ratio of 2.22 and a current ratio of 2.22. The stock has a market capitalization of $42.77 million, a P/E ratio of -0.75 and a beta of 2.02.

Cue Biopharma (NASDAQ:CUE) last issued its earnings results on Friday, March 28th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.01. Cue Biopharma had a negative net margin of 468.02% and a negative return on equity of 156.38%. The business had revenue of $1.80 million for the quarter, compared to the consensus estimate of $1.70 million. During the same quarter last year, the firm posted ($0.28) EPS. Equities analysts forecast that Cue Biopharma, Inc. will post -0.76 earnings per share for the current year.

Cue Biopharma Profile

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.